Carl Zeiss Meditec AG / Key word(s): Alliance 22.12.2014 20:24 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Carl Zeiss Meditec invests in innovative radiotherapy solution for wet age- related macular degeneration Jena, 22 December 2014: Carl Zeiss Meditec Inc., a 100%-owned subsidiary of Carl Zeiss Meditec AG (ISIN: DE0005313704) has signed a collaboration agreement with Oraya Therapeutics Inc., Newark, USA (Oraya). Over the past few years, Oraya has developed the novel low energy radiation therapy "Oraya Therapy" for wet age-related macular degeneration (wet AMD) and introduced it to the market. Under the terms of the agreement, Carl Zeiss Meditec will provide funding to Oraya for the implementation of its growth strategy over a period of up to two years and in turn receive rights for a participation in the company reaching up to a majority stake after two years. The amount of the funding provided to Oraya has not been disclosed. Carl Zeiss Meditec expects this investment to further strengthen its role as global innovation leader in ophthalmology as well as its existing portfolio of solutions for diagnosis and therapy of eye diseases. Contact for investors Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG Tel. +49 3641 220-116, E-Mail: investors.meditec@zeiss.com Press contact Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG Tel. +49 3641 220-331, E-Mail: press.meditec@zeiss.com 22.12.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Carl Zeiss Meditec AG Göschwitzer Str. 51-52 07745 Jena Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: investors.meditec@zeiss.com,info.meditec@zeiss.com Internet: www.meditec.zeiss.de ISIN: DE0005313704 WKN: 531370 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Carl Zeiss Meditec invests in innovative radiotherapy solution for wet age-related macular degeneration
| Source: EQS Group AG